E
CLDI icon

Ergoteles’s Calidi Biotherapeutics CLDI Stock Holding History

Ergoteles’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-159
Closed -$196K – 1104
2023
Q1 		$196K Sell
159
-338
-68% -$414K 0.01% 1014
2022
Q4 		$607K Buy
497
+229
+85% +$274K 0.02% 632
2022
Q3 		$317K Buy
+268
New +$321K 0.01% 953

Other funds holding CLDI

Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
EC
Elequin Capital New York $1.19B AUM 16.08% 1-Year Est. Return

Ergoteles's CLDI Position: Q2 2023 in Review

Ergoteles sold out of Calidi Biotherapeutics (CLDI) in Q2 2023, closing a stake of 159 shares — an estimated $196K sold.

Ergoteles first reported a position in CLDI in Q3 2022 and held it in 3 quarters. The position peaked at $607K in Q4 2022. 24 funds tracked by Wall St. Rank hold CLDI as of Q2 2023.

  • Ergoteles reported no remaining Calidi Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 159 Calidi Biotherapeutics shares in Q2 2023, an estimated $196K.
  • Ergoteles first reported a position in Calidi Biotherapeutics in Q3 2022 and held it in 3 quarters.
  • Ergoteles's Calidi Biotherapeutics position peaked at $607K in Q4 2022.
  • 24 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.